Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Check Point Software Technologies Ltd (CHKP) vs GeneDx Holdings Corp (WGS) Price & Performance

Check Point Software Technologies LtdTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Check Point Software Technologies Ltd vs GeneDx Holdings Corp — how do they compare? Check Point Software Technologies Ltd trades at $129.5 (market cap $13.18B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Check Point Software Technologies Ltd is far larger — about 5.4× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.

CHKPWGS
Market Cap
$13.18B$2.44B
Sector
TechnologyTechnology
52-Week High
$206.91$167.51
52-Week Low
$112.47$34.51
Enterprise Value
$12.88B$2.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Check Point Software Technologies Ltd

CHKP trades at $129.29, down 1.41% today, with a bearish technical signal as it hovers near support at $128. The stock shows strong fundamentals with a P/E of 13.24, net income margin of 37.93%, and consistent earnings beats in recent quarters. Recent news highlights AI security growth potential and insider selling activity.

The outlook is mixed: valuation appears attractive with a consensus price target of $146.92, but near-term risks include competitive pressures and margin declines. Upside depends on AI-driven revenue acceleration in 2027, while downside is capped by solid cash flow and profitability.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.

Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.

Returns comparison

Trailing returns across standard periods

About Check Point Software Technologies Ltd

Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.

Read more on CHKP

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS